Elanco lifts 2026 outlook as Zenrelia and Credelio Quattro power growth
Aug 5, 2026, 6:29 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The raised guidance, margin expansion, and leverage reduction signal stronger fundamentals and optionality for capital allocation, which historically supports multiple expansion when investors view risk as contained. Key peers have shown stock bumps on similar earnings-driven upgrades; ELAN could join with a near-term upside cap if execution remains on track.
AI summary
What happened, with direct paths to the underlying reporting
Elanco posted strong Q2 results, boosting full-year targets as Zenrelia and Credelio Quattro deliver growth. The AHV International acquisition closed, contributing to a more diverse portfolio, while margin expansion and debt leverage improvements support a higher guidance trajectory. With FX tailwinds and ongoing price discipline, Elanco aims for 3x-style leverage and solid earnings progress into 2027.
Q2 2026 revenue $1,368M, +10% YoY; organic CC growth 8%.
Zenrelia and Credelio Quattro drive growth; AHV acquisition closed in April 2026.
Adjusted EBITDA $1.01B-$1.035B; Adj EPS $1.10-$1.16; leverage ~3.0x by 2027.
Elanco Ascend delivering efficiency; net leverage at 3.1x end of Q2 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Elanco posted a strong Q2 with revenue of $1.368B, up 10% YoY and 8% organic CC, driven by Zenrelia and Credelio Quattro. The company lifted full-year guidance and highlighted fas…
Jim Cramer's Lightning Round highlighted ELAN as his preferred pick in animal health, potentially sparking renewed investor interest. The endorsement comes alongside Zoetis' leade…
Elanco Animal Health exceeded Q1 earnings expectations with adjusted earnings of 40 cents, driven by robust sales growth and expanding guidance for the full year. The company’s po…
Jim Cramer recommended buying Elanco for its positive turnaround. Barclays initiated coverage with an Overweight rating and $30 price target. Elanco shares have seen a recent 1.8%…
